MAPK3 and lung adenocarcinoma: NCS 613 targets PDE4 and, indirectly, p38 MAPK as well as NF-κB and ERK1/2 signaling, leading to a down-regulation of inflammation in both the human A549 cell line and lung adenocarcinoma explants.